Court awards TwinStrand $245.2M in Guardant Health patent case

Go back to Court awards TwinStrand $245.2M in Guardant Health patent case

TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued R

August 24, 2026 7:00 AM EDT

Court preserves 2023 willful infringement verdict and orders a 6% royalty on sales of 11 Guardant Health products and services found to infringe two patents underlying TwinStrand Duplex Sequencing® technology

Court enters judgment in favor of TwinStrand and the University of Washington on validity of the asserted claims of both patents

SEATTLE--(BUSINESS WIRE)-- TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their... More